Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // September 14th, 2011 // 7:03 am
Rise and shine, everyone, another day is on the way. And here on the Pharmalot corporate campus, we are celebrating with, yes, a cup of stimulation as we brace for a busy few hours. We are hosting a webinar later on Social Media and the FDA and welcome you to join us. This means we will take a brief respite from the usual routine, but return shortly to perusing documents and hunting for interesting items. Meanwhile, have a great day and stay in touch…
Pfizer Delays Formula Unit Sale To Explore Spin-Off (Bloomberg News)
Teva Boosts Stake In CureTech On Lymphoma Data (PharmaTimes)
Albemarle To Raise API Prices Over ‘Regulatory Costs’ (InPharma Technologist)
Eisai Says Aricept Patent Is Upheld By Japan Court (Bloomberg News)
J&J Exec Will Become Boston Scientific CEO (Reuters)
Boehringer Ingelheim Expands Connecticut Facility (Ridgefield Press)
Lilly Uses Internet To Broaden Research Reach (InformationWeek)
EDITOR’S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Active Pharmaceutical Ingredients, Albemarle, API, Aricept, Boehringer Ingelheim, Boston Scientific, CureTech, Eisai, Eli Lilly, Infant Formula, Japan, JJ, Johnson & Johnson, Lymphoma, Patents, Pfizer, Teva Pharmaceuticals